Decitabine and Anti-PD-1 in R/R DLBCL

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 15, 2023

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2026

Conditions

Diffuse Large B Cell LymphomaRelapse/RecurrenceExtranodal ExtensionCentral Nervous System Lymphoma

Interventions

DRUG

Low-Dose Decitabine plus anti-PD-1

Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8

Trial Locations (1)

RECRUITING

ChinaPLAGH, Beijing

All Listed Sponsors

lead

Chinese PLA General Hospital

OTHER